Evidence map›Paper›PMID 33094484›Full record

ArticleMuscle & nerve2021

Autoantibodies in Japanese patients with ocular myasthenia gravis.

Akiko Nagaishi, Tomoko Narita, Mark Woodhall, Leslie Jacobson, Patrick Waters, Sarosh R Irani, Angela Vincent, Hidenori Matsuo

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Muscle & nerve, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Myasthenia gravis: the future is here.The Journal of clinical investigation · 2024
    Review
  3. Immunotherapy for ocular myasthenia gravis: an observational study in Japan.Therapeutic advances in neurological disorders · 2023
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Akiko NagaishiDepartment of Neurology, Nagasaki Kawatana Medical Center, Nagasaki, Japan.
Tomoko NaritaDepartment of Neurology, Nagasaki Kawatana Medical Center, Nagasaki, Japan.
Mark WoodhallNuffield Department of Clinical Neurosciences, Oxford Autoimmune Neurology Group, University of Oxford, Oxford, UK.
Leslie JacobsonNuffield Department of Clinical Neurosciences, Oxford Autoimmune Neurology Group, University of Oxford, Oxford, UK.
Patrick WatersNuffield Department of Clinical Neurosciences, Oxford Autoimmune Neurology Group, University of Oxford, Oxford, UK.
Sarosh R IraniNuffield Department of Clinical Neurosciences, Oxford Autoimmune Neurology Group, University of Oxford, Oxford, UK.
Angela VincentNuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Hidenori MatsuoDepartment of Neurology, Nagasaki Kawatana Medical Center, Nagasaki, Japan.
University of Oxford · GBNagasaki Kawatana Medical Center · JP

Funding

Wellcome Trust 104079/Z/14/Z
6 · The paper itself

Abstract

introductionThe majority of patients with myasthenia gravis (MG) initially present with ocular symptoms, but it is difficult to predict which cases will remain as ocular MG (OMG) or will progress to generalized MG. Herein we evaluated the serologic profile of Japanese OMG and its relationship with clinical features.

methodsSeventy-three patients with OMG from five Japanese myasthenia gravis (MG) centers were enrolled. Live cell-based assays (CBAs) were used to determine the presence of autoantibodies (Abs) to clustered adult (2α, β, δ, ε) and fetal (2α, β, δ, γ) acetylcholine receptor (AChR) isoforms, muscle-specific receptor tyrosine kinase (MuSK), and lipoprotein receptor-related protein-4 (LRP4).

resultsThirty-four of 73 (46.5%) serum samples were positive for Abs against both the adult-type and fetal-type AChR, as expected, but 7 (9.6%) and 2 (2.7%) were positive only for fetal or adult AChR-Abs, respectively. Four (5.4%) samples were positive for MuSK-Abs, but two of these also contained antibodies to fetal AChR or LRP4. Twenty-six (35.6%) samples were seronegative. DISCUSSION: Abs against fetal-specific AChR, MuSK, and LRP4 are found in some patients with OMG. Future studies attempting to predict conversion from ocular symptoms to generalized MG may benefit from measurement of these antibodies.

Indexed as

AdolescentAdultAgedAged, 80 and overAsian PeopleAutoantibodiesBlepharoptosisChildChild, PreschoolDiplopiaFacial MusclesFemaleHEK293 CellsHumansJapanLDL-Receptor Related ProteinsAutoantibodiesLDL-Receptor Related ProteinsLRP4 protein, humanMUSK protein, humanProtein IsoformsReceptor Protein-Tyrosine KinasesReceptors, Cholinergicanti-acetylcholine receptor antibody, cell-based assays, LRP4, MuSK, ocular myasthenia gravis

Identifiers

PMID33094484
PMCPMC7983878
OpenAlexW3093711780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.